- Home
- ACR vs PLX Comparison
ACR vs PLX Comparison
Compare ACR & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACR
- PLX
- Stock Information
- Founded
- ACR 2005
- PLX 1993
- Country
- ACR United States
- PLX United States
- Employees
- ACR N/A
- PLX N/A
- Industry
- ACR Real Estate Investment Trusts
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACR Real Estate
- PLX Health Care
- Exchange
- ACR Nasdaq
- PLX Nasdaq
- Market Cap
- ACR 154.7M
- PLX 160.2M
- IPO Year
- ACR N/A
- PLX 1998
- Fundamental
- Price
- ACR $18.41
- PLX $1.73
- Analyst Decision
- ACR Buy
- PLX Strong Buy
- Analyst Count
- ACR 2
- PLX 1
- Target Price
- ACR $17.50
- PLX $15.00
- AVG Volume (30 Days)
- ACR 31.8K
- PLX 1.0M
- Earning Date
- ACR 04-30-2025
- PLX 05-09-2025
- Dividend Yield
- ACR N/A
- PLX N/A
- EPS Growth
- ACR N/A
- PLX N/A
- EPS
- ACR 0.34
- PLX 0.04
- Revenue
- ACR $83,545,000.00
- PLX $59,764,000.00
- Revenue This Year
- ACR $8.36
- PLX $65.02
- Revenue Next Year
- ACR N/A
- PLX $57.34
- P/E Ratio
- ACR $54.27
- PLX $40.01
- Revenue Growth
- ACR 6.92
- PLX 0.18
- 52 Week Low
- ACR $12.33
- PLX $0.82
- 52 Week High
- ACR $23.81
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- ACR 46.30
- PLX 27.30
- Support Level
- ACR $18.30
- PLX $2.70
- Resistance Level
- ACR $19.10
- PLX $2.93
- Average True Range (ATR)
- ACR 0.79
- PLX 0.21
- MACD
- ACR 0.13
- PLX -0.08
- Stochastic Oscillator
- ACR 52.44
- PLX 0.36
About ACR ACRES Commercial Realty Corp.
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.